Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q1 2017 · 10-Q
Revenue$288.49K$288.49K−84.5% vs Q1 2016 Net Income-$383.57K-$383.57KN/M vs Q1 2016 EPS Diluted-$0.02-$0.02N/M vs Q1 2016 Operating Income-$318,805N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
Free Cash Flowderived$199,802N/M Margins · derivedOperating margin-110.5%−96.7 pt vs Q1 2016
Net margin-133.0%−112.4 pt vs Q1 2016
ended Jun 30, 2016 · filed Aug 16, 2016 · 47 d after period end